Yanan Zhu
Stock Analyst at Wells Fargo
(2.18)
# 1,769
Out of 5,106 analysts
86
Total ratings
38.57%
Success rate
-0.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Overweight | $80 → $60 | $24.18 | +148.14% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $17 → $12 | $9.42 | +27.39% | 7 | Nov 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $50 → $45 | $22.00 | +104.55% | 7 | Nov 5, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $48 → $72 | $35.40 | +103.39% | 7 | Nov 3, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $6.43 | +211.04% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.19 | +82.65% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $35.95 | +25.17% | 1 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $77 → $82 | $80.33 | +2.08% | 3 | Aug 22, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $16 → $12 | $1.72 | +597.67% | 4 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $7.5 → $8 | $5.71 | +40.11% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $0.98 | +155.94% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.64 | +204.88% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $2.82 | +396.45% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $72.14 | +3.96% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $27.77 | +152.07% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.99 | +150.63% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $33.23 | +20.37% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $56.46 | +15.13% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $9.22 | +225.38% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.43 | +830.23% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.40 | +13,135.29% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $845.95 | -61.46% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.20 | +586.27% | 2 | Oct 29, 2020 |
uniQure
Nov 12, 2025
Maintains: Overweight
Price Target: $80 → $60
Current: $24.18
Upside: +148.14%
Intellia Therapeutics
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $17 → $12
Current: $9.42
Upside: +27.39%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $22.00
Upside: +104.55%
RAPT Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $48 → $72
Current: $35.40
Upside: +103.39%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $6.43
Upside: +211.04%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.19
Upside: +82.65%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $35.95
Upside: +25.17%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $77 → $82
Current: $80.33
Upside: +2.08%
Metagenomi
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.72
Upside: +597.67%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Overweight
Price Target: $7.5 → $8
Current: $5.71
Upside: +40.11%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $0.98
Upside: +155.94%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.64
Upside: +204.88%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.82
Upside: +396.45%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $72.14
Upside: +3.96%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $27.77
Upside: +152.07%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.99
Upside: +150.63%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $33.23
Upside: +20.37%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $56.46
Upside: +15.13%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $9.22
Upside: +225.38%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.43
Upside: +830.23%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $3.40
Upside: +13,135.29%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $845.95
Upside: -61.46%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.20
Upside: +586.27%